A report released earlier today by HSBC about Gerresheimer (ETR:GXI) bumps the target price to 72.00EUR
- Updated: October 16, 2016
Gerresheimer (ETR:GXI) had its price target upped to 72.00EUR by HSBC in a report announced 10/12/2016. The bumped up target price indicates a possible upside of 0.01% based on the company's most recent stock price close.
Previously on 10/11/2016, HSBC reported about Gerresheimer (ETR:GXI) increased the target price from 0.00EUR to 72.00EUR. At the time, this indicated a possible upside of 0.01%.
Having a price of 71.20EUR, Gerresheimer (ETR:GXI) traded 0.00% even on the day. The last close is up 0.00% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time. GXI has recorded a 50-day average of 0.00EUR and a two hundred day average of 0.00EUR. Volume of trade held steady, with 0 shares of GXI changing hands on par with the typical 0
Recent Performance Chart
Gerresheimer has 52 week low of 0.00EUR and a one year high of 0.00EUR and has a market cap of 0 EUR.
General Information About Gerresheimer (ETR:GXI)
Gerresheimer AG is a Germany-based company that operates in the pharmaceuticals and health care industry. It is structured in three business segments: Plastic and Devices, Primary Packaging Glass and Life Science Research. The Company produces pharmaceutical packaging products, as well as drug-delivery systems made out of glass and plastics or a combination of both. Its product portfolio includes insulin pens, inhalers, pre-fillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, plus cosmetic packaging products. The Company operates approximately 40 production facilities in Europe, North America, South America and Asia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.